Vertex Pharmaceuticals saw its share price rise by approximately 14% in the last quarter, a significant move considering the broader market's recent 1% decline. The company's legal challenges ...

Investors eye Vertex’s Q1 for Alyftrek and Journavx momentum amid Trikafta’s international headwinds. Vertex stock shows a bullish technical bias despite recent pullback and mixed short-term ...

ToolGen, Inc. a global leader in genome editing technology, announced that it has filed a patent infringement lawsuit in the United Kingdom against Vertex Pharmaceuticals and its commercial ...

(Freepik) Vertex Ventures’ Southeast Asia and India-focused fund has ramped up its investment activity in India, with a focused approach on AI-led businesses, fintech, and consumer brands.

An agrivoltaics power plant on the plateau of Guizhou province, southwestern China, has been connected to the grid using Trinasolar Vertex N 720W series modules. With a total capacity of 67.5MW ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock. Vertex Pharmaceuticals (NASDAQ: VRTX) had a fine Tuesday ...

In another departure from its core focus on genetic medicines, Vertex Pharma has agreed a $4.9 billion purchase of Alpine Immune Sciences, adding a mid-stage drug candidate for kidney disease IgA ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

Political outrage led by Pennsylvania Gov. Josh Shapiro over sharply higher electricity costs led to negotiations and a price cap. Federal regulators late Monday approved price controls for PJM ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...